Immunowake develops a universal cancer vaccine that generates safer and more effective bi-specific antibodies, waking up the patient's immune system to recognize and kill cancer cells. Their strategy involves harnessing the body's immune system to target cancer cells, reducing toxicity while maintaining anti-tumor efficacy. They focus on identifying new therapies for patients who do not respond to existing treatments, using recent breakthroughs in cancer immunotherapy to activate antigen-specific T-cells.